Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs
- PMID: 38134880
- DOI: 10.1016/j.chembiol.2023.11.014
Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs
Abstract
EP300/CBP are histone acetyltransferases recruited onto chromatin by oncogenic transcription factors and control the transcriptional program via their activity in enhancer areas. In the December issue of Cancer Cell, Nicosia et al.1 offer new promise in targeting EP300/CBP using the small-molecule inhibitor CSS1477 in patients with blood tumors and no other therapeutic options.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests L.K.X. is an employee of AstraZeneca.
Comment on
-
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.Cancer Cell. 2023 Dec 11;41(12):2136-2153.e13. doi: 10.1016/j.ccell.2023.11.001. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995682
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
